Vogenx (NASDAQ:VOGX) Posts Quarterly Earnings Results

Vogenx (NASDAQ:VOGX) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, Zacks reports.

Vogenx Stock Down 4.8%

Shares of VOGX opened at $32.50 on Friday. Vogenx has a 1-year low of $12.95 and a 1-year high of $38.41.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. JonesTrading started coverage on shares of Vogenx in a research note on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a research note on Saturday, August 22nd. Finally, WBB Securities began coverage on shares of Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and an average target price of $48.50.

Vogenx Company Profile

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.